Dr Milan Anjanappa

Consultant Clinical Oncologist : Prostate Cancer Specialist Dr. Milan Anjanappa is a Consultant Clinical Oncologist specialising in the non-surgical treatment of prostate and complex urological cancers. He has over a decade of experience, having qualified as an Oncologist in 2015.  His aim is simple - to provide the highest standard of personalised cancer care while helping patients make confident, informed decisions about their treatment.  He has a busy NHS practice based at Mount Vernon Cancer Centre in London, one of the UK's leading specialist cancer centres. He sees many complex cases and delivers advanced, personalised treatment using the latest radiotherapy and systemic therapies.  His private practice focuses on comprehensive care for men with prostate cancer, offering expert guidance and modern treatment options, including advanced radiotherapy techniques, hormone therapy, chemotherapy, immunotherapy, and targeted therapies, particularly for complex or challenging cases.  Dr Anjanappa specialises in the management of prostate cancer at all stages, from newly diagnosed early disease through to advanced and recurrent cancer.  He has extensive expertise in state-of-the-art, non-surgical cancer treatments such as radiotherapy and systemic treatments, including:  * Precision radiotherapy techniques (image-guided, stereotactic, MR-guided)  * Prostate brachytherapy (high-dose-rate and low-dose-rate seeds)  * Systemic therapies such as hormone therapy, chemotherapy, immunotherapy, and targeted treatments  * Innovative therapies including Lutetium-PSMA radioligand therapy for advanced prostate cancer  Dr. Anjanappa's approach allows treatments to be used alone or in combination, tailored to the patient's individual needs.  He is particularly experienced in treating patients who:  *Are exploring alternatives to surgery  * Have complex or recurrent prostate cancer  *Require advanced radiotherapy techniques  * Are seeking highly individualised treatment planning or a second opinion  His expertise in advanced radiotherapy and targeted therapies ensures cancer is treated as effectively as possible while minimising side effects and preserving quality of life.  Dr Anjanappa is actively involved in clinical research aimed at improving outcomes for patients with prostate cancer.  He has participated in numerous clinical trials and research studies as both Principal Investigator and Sub-Investigator.  He has published in peer-reviewed medical journals and presented at national and international conferences.  Dr Anjanappa is recognised by colleagues and patients alike for his thoughtful, thorough and compassionate care.  Patients value his willingness to spend time explaining complex medical information in a clear and understandable way. 

Prostate cancer; prostate cancer brachytherapy; prostate seed brachytherapy; prostate cancer Lutetium-177 PSMA therapy; prostate HDR brachytherapy; prostate cancer SABR/SBRT; SABR/SBRT; 5-day prostate radiotherapy; MR Linac; Kidney SABR/SBRT; radiotherapy; IMRT/IGRT; prostate cancer chemotherapy; prostate cancer hormone therapy; immunotherapy; bladder cancer; Oligo-metastasis SABR/SBRT